A Study to Evaluate a New Drug for Patients with Mild to Moderate Alzheimer’s Disease

What we are studying

The purpose of this research study is to determine whether an investigational drug, is safe and beneficial in delaying or altering the decline in memory and daily functioning when given to people with Alzheimer’s disease (AD). The U.S. Food and Drug Administration (FDA) has not approved the investigational drug for the treatment of AD and we do not know whether daily use can change the course of the disease.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 55 - 85

Eligibility Criteria

  • With probable Alzheimer's Disease
  • Must be receiving donepezil treatment for at least 6 months prior to baseline and be on a stable dose for 3 months prior to baseline
  • Have had a brain MRI or CT scan consistent with Alzheimer's disease
  • Study partner willing to accompany the participant to all clinic visits and participate in evaluations.

What is involved

  • 12 - 15 visits to the Sticht Center over the next 14 months
  • 2 MRI scans
  • Tests of memory and thinking
  • ECG
  • Blood and urine tests
  • Collection of vital signs
  • Optional lumbar puncture
  • Take the study drug or placebo once a day for 52 weeks. Extension study includes visits at week 56
  • 64
  • 72
  • 80
  • 84.


Participants will receive up to $2500 for completing all study visits. If they choose to participate in the add on study, they will receive an additional $775 if all visits are complete.

Contact Information

Study Coordinator
Marjorie Gillet
Principal Investigator
Kaycee Sink, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.